Thiabendazole: a potential adjuvant in cancer therapy

Area of Science:

• Immunology
• Pharmacology

Background:

• Delayed hypersensitivity is a critical immune response.
• Immunosuppression from radiation and chemotherapy impairs immune function.
• Thiabendazole (TBZ) is a thiazole derivative with potential immunomodulatory properties.

Purpose of the Study:

• To evaluate the effects of thiabendazole (TBZ) on delayed hypersensitivity.
• To assess TBZ's impact on normal, tumor-bearing, and immunosuppressed mice.
• To explore TBZ's potential as an adjunct in cancer therapy.

Main Methods:

• Administered TBZ intraperitoneally to mice.
• Challenged mice with 2,4-dinitrochlorobenzene (DNCB) to assess delayed hypersensitivity.
• Utilized spleen cells and macrophages for immune transfer studies.
• Investigated TBZ's effects on radiation and Adriamycin-induced immunosuppression.

Main Results:

• TBZ treatment increased foot pad swelling by 41% in normal mice.
• Enhanced immune reactivity was transferable via spleen cells and macrophages.
• TBZ restored 90% of the delayed hypersensitivity response in irradiated mice.
• TBZ reversed immunosuppressive effects of Adriamycin.

Conclusions:

• Thiabendazole (TBZ) amplifies immune function in multiple spleen cell populations.
• TBZ demonstrates significant potential as an adjunct in cancer therapy.
• Further research into TBZ's immunomodulatory mechanisms is warranted.